Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10839866 | 0.87 | KDM4E (0.65) | KDM4EHPGDALDH1A1CNR2CNR1 | |
| SCHEMBL62162 | 0.85 | CLEC4M (0.52) | KDM4EHPGDALDH1A1CNR2CNR1 | |
| SCHEMBL4308337 | 0.76 | KDM4E (0.49) | KDM4EHPGDALDH1A1HSD17B10MAPT | |
| SCHEMBL4308193 | 0.76 | CYP1A2 (0.50) | KDM4EHPGDALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL16597393 | 0.74 | KDM4E (0.52) | KDM4EHPGDALDH1A1CNR2CNR1 | |
| SCHEMBL7509122 | 0.73 | KDM4E (1.00) | KDM4EHPGDALDH1A1CNR2CYP1A2 | |
| SCHEMBL9829849 | 0.73 | CLEC4M (0.56) | KDM4EHPGDALDH1A1CNR2CNR1 | |
| Ammonia Solution, Strong SCHEMBL28187483 | 0.72 | ALDH1A1 (0.97) | KDM4EHPGDALDH1A1CNR2CYP1A2 | |
| Hydrochloric Acid SCHEMBL30353212 | 0.72 | ALDH1A1 (0.97) | KDM4EHPGDALDH1A1CNR2CYP1A2 | |
| Fluoride SCHEMBL5823412 | 0.71 | ALDH1A1 (0.94) | KDM4EHPGDALDH1A1CNR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-1633362-B1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8129382-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7750008-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-12-03 | — | — | US | disclosed |
| US-7601719-B2 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | MGI GP, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7456178-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7268138-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20050020595-A1 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | PARP1, PARP2, NLRP3 | KDM4E 2880/4885HPGD 498/4885ALDH1A1 326/4885 |
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | KDM4E 1640/4885HPGD 291/4885ALDH1A1 865/4885 |
| US-20050020595-A1 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | PARP1, PARP2, PARP3 | KDM4E 1571/4885HPGD 326/4885ALDH1A1 882/4885 |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | KDM4E 1571/4885HPGD 326/4885ALDH1A1 882/4885 |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | PARP1, PARP2, PARP11 | KDM4E 297/4885HPGD 971/4885ALDH1A1 481/4885 |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | KDM4E 1571/4885HPGD 326/4885ALDH1A1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.